Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

325 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report.
Hartung HP, Polman C, Bertolotto A, Deisenhammer F, Giovannoni G, Havrdova E, Hemmer B, Hillert J, Kappos L, Kieseier B, Killestein J, Malcus C, Comabella M, Pachner A, Schellekens H, Sellebjerg F, Selmaj K, Sorensen PS. Hartung HP, et al. Among authors: schellekens h. J Neurol. 2007 Jul;254(7):827-37. doi: 10.1007/s00415-006-0486-3. Epub 2007 Apr 24. J Neurol. 2007. PMID: 17457510 Review.
Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis.
Polman CH, Bertolotto A, Deisenhammer F, Giovannoni G, Hartung HP, Hemmer B, Killestein J, McFarland HF, Oger J, Pachner AR, Petkau J, Reder AT, Reingold SC, Schellekens H, Sørensen PS. Polman CH, et al. Among authors: schellekens h. Lancet Neurol. 2010 Jul;9(7):740-50. doi: 10.1016/S1474-4422(10)70103-4. Lancet Neurol. 2010. PMID: 20610349
Re: Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
Polman CH, Deisenhammer F, Giovannoni G, Killestein J, Schellekens H. Polman CH, et al. Among authors: schellekens h. Neurology. 2007 Oct 9;69(15):1553-4; author reply 1555. doi: 10.1212/01.wnl.0000295671.79239.f1. Neurology. 2007. PMID: 17923619 No abstract available.
The Rebif new formulation story: it's not trials and error.
Jaber A, Driebergen R, Giovannoni G, Schellekens H, Simsarian J, Antonelli M. Jaber A, et al. Among authors: schellekens h. Drugs R D. 2007;8(6):335-48. doi: 10.2165/00126839-200708060-00002. Drugs R D. 2007. PMID: 17963425 Review.
325 results